VanEck Biotech ETF
BBH
108 hedge funds and large institutions have $132M invested in VanEck Biotech ETF in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 38 reducing their positions, and 18 closing their positions.
0.67% less ownership
Funds ownership: 30.64% → 29.97% (-0.67%)
5% less capital inflows, than outflows
Capital inflows: $18.9M | Capital outflows: $19.8M
6% less funds holding
Funds holding: 115 → 108 (-7)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
63% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 38
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$11.5M |
| 2 |
Cetera Advisor Networks
El Segundo,
California
|
+$1.08M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$992K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$923K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$693K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.69M |
| 2 |
Goldman Sachs
New York
|
-$2.68M |
| 3 |
Lugano Financial Advisors SA (LFA)
Lugano,
Switzerland
|
-$1.35M |
| 4 |
Norris Financial Group
Greenville,
South Carolina
|
-$1.24M |
| 5 |
Wealthspire Advisors (New York)
New York
|
-$1.18M |
BBH Hedge Fund Activity: Q2 2022 in Review
108 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2022, worth a combined $132M — down 11% from $147M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BBH and 14 opened new positions — a net loss of 4 holders — while 38 trimmed existing stakes and 14 added.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $11.5M. The largest seller was Susquehanna International Group, cutting an estimated $2.69M.
- 108 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2022, down from 115 in Q1 2022.
- Funds reported $132M of VanEck Biotech ETF stock for Q2 2022, down 11% quarter-over-quarter.
- 14 funds opened new VanEck Biotech ETF positions in Q2 2022 and 18 closed out, a net change of -4 holders.
- The largest VanEck Biotech ETF buyer in Q2 2022 was JP Morgan Chase, an estimated $11.5M added.
- The largest VanEck Biotech ETF seller in Q2 2022 was Susquehanna International Group, an estimated $2.69M sold.
Based on aggregated 13F filings for Q2 2022.